Nima Farzan
Insider Reports History
- Location
- Lexington, MA
- Signature
- /s/ Keith Regnante, Attorney-in-Fact
- All insider transactions
- Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date
Holdings reported by Nima Farzan:
| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Keros Therapeutics, Inc. | Director | Common Stock | 5,250 | $75,810 | $14.44 | 04 Jun 2025 | Direct |
| Kinnate Biopharma Inc. | CHIEF EXECUTIVE OFFICER, Director | Common Stock | 0 | $0 | $2.59 | 03 Apr 2024 | Direct |
| Keros Therapeutics, Inc. | Director | Stock Option (right to buy) | 10,500 | 04 Jun 2025 | Direct | ||
| Kinnate Biopharma Inc. | CHIEF EXECUTIVE OFFICER, Director | Stock Option (right to buy) | 0 | 03 Apr 2024 | Direct |
Insider Reports Filed by Nima Farzan
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| KROS | Keros Therapeutics, Inc. | 04 Jun 2025 | 2 | $0 | 4 | Director | 06 Jun 2025, 16:15 |
| KROS | Keros Therapeutics, Inc. | 30 May 2024 | 1 | $0 | 4 | Director | 03 Jun 2024, 16:15 |
| /report/000141588924010433-farzan-nima-2024-04-03 | Kinnate Biopharma Inc. | 03 Apr 2024 | 6 | $0 | 4 | CHIEF EXECUTIVE OFFICER, Director | 05 Apr 2024, 16:55 |
| KROS | Keros Therapeutics, Inc. | 06 Jun 2023 | 1 | $0 | 4 | Director | 08 Jun 2023, 16:38 |
| /report/000120919123009620-farzan-nima-2023-02-10-restatement | Kinnate Biopharma Inc. | 10 Feb 2023 | 1 | $0 | 4/A | Chief Executive Officer, Director | 15 Feb 2023, 10:01 |
| KROS | Keros Therapeutics, Inc. | 01 Jun 2022 | 1 | $0 | 4 | Director | 03 Jun 2022, 16:24 |
| /report/000120919122009740-farzan-nima-2022-02-11 | Kinnate Biopharma Inc. | 11 Feb 2022 | 1 | $0 | 4 | Chief Executive Officer, Director | 15 Feb 2022, 15:00 |
| KROS | Keros Therapeutics, Inc. | 01 Jun 2021 | 1 | $0 | 4 | Director | 03 Jun 2021, 17:29 |